Abstract
Because of high occurrence of side effects of conventional anticancer drugs, new therapies have been widely studied, such as the use of non-usual molecules and the association with nanomaterials. In this context, sildenafil is a molecule that has been lately considered as a co-adjuvant in cancer therapy because it inhibits an enzyme with a potential role in tumor progression, phosphodiesterase-5. Taking into account the combination of nanoparticles and sildenafil, we produced systems based on mesoporoussilica nanoparticles, Pluronic F-127 and sildenafil as the main therapy for prostate cancer.
Highlights
A major problem in cancer treatments is the high incidence of side effects intrinsic to anticancer drugs, which end up affecting the patients' lives and the therapies themselves
To get preliminary results of the antitumor potential of the association of SIL, mesoporous silica nanoparticles (MSNs) and PF-127, we developed three systems that differed only by the MSNs concentration and treated rats with chemically induced prostate cancer
Preliminary macroscopic analyses showed an interesting decrease in frequency of metastasis and prostatic lesions that was proportional to MSNs concentration
Summary
A major problem in cancer treatments is the high incidence of side effects intrinsic to anticancer drugs, which end up affecting the patients' lives and the therapies themselves. In an attempt to overcome this issue, the association of these drugs with non-usual molecules that act through different mechanisms as well as the association with nanomaterials are promising alternatives. In this way, sildenafil (SIL) is a molecule that inhibits an enzyme which expression is increased in many carcinomas, phosphodiesterase-5 (PDE-5) [1]. Mesoporous silica nanoparticles (MSNs) are good candidates to be used as drug carriers once they are safe and biocompatible [4] They have high superficial area and great pore volume, very appropriate to carry bioactives [4]. They provide a sustained release of the drug, preventing it of premature degradation and increasing the effectiveness of drug delivery [4,5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
